12:15 PM
 | 
May 10, 2019
 |  BioCentury  |  Emerging Company Profile

HopeMed: Targeting PRLR for chronic diseases

How HopeMed’s anti-PRLR antibody could treat endometriosis, alopecia with fewer side effects

HopeMed spun out of Peking University last month with a mAb against the prolactin receptor from Bayer that could provide a safe alternative to competing therapies for endometriosis and alopecia.

Hope Medicine Inc. has exclusive worldwide rights from Bayer AG to develop and commercialize the mAb, BAY 1158061, for endometriosis, male and female pattern hair loss and other chronic diseases with dysregulated PRL signaling.

Although the underlying causes of endometriosis are not clear, high serum levels of the hormone PRL are associated with the disease. According to HopeMed, undisclosed data from Bayer suggest PRL-PRLR signaling also plays a role in alopecia. Rui-Ping Xiao said HopeMed is continuing to investigate the role of PRL-PRLR signaling in the diseases. Xiao is co-founder, chairwoman and CEO of the spinout and founding director of Peking University’s Institute of Molecular Medicine.

Bayer partnered with Xiao’s lab to develop the mAb for alopecia, and showed in a...

Read the full 748 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >